Advisory Research’s Ascendis Pharma A/S ASND Stock Holding History

Advisory Research’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,276	Closed	-$2.55M	–	341
2020 Q4	$2.55M	Buy	15,276 +3,444	+29%	+$570K	0.19%	103
2020 Q3	$1.83M	Sell	11,832 -2,635	-18%	-$379K	0.18%	110
2020 Q2	$2.14M	Buy	14,467 +1,204	+9%	+$165K	0.19%	108
2020 Q1	$1.49M	Sell	13,263 -2,713	-17%	-$353K	0.1%	105
2019 Q4	$2.22M	Buy	15,976 +2,218	+16%	+$246K	0.1%	118
2019 Q3	$1.32M	Sell	13,758 -4,688	-25%	-$523K	0.06%	155
2019 Q2	$2.12M	Buy	18,446 +2,172	+13%	+$260K	0.04%	187
2019 Q1	$1.92M	Sell	16,274 -971	-6%	-$85K	0.04%	191
2018 Q4	$1.08M	Buy	17,245 +5,412	+46%	+$340K	0.02%	232
2018 Q3	$838K	Buy	+11,833	New	+$815K	0.01%	270

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Advisory Research's ASND Position: Q1 2021 in Review

Advisory Research sold out of Ascendis Pharma A/S (ASND) in Q1 2021, closing a stake of 15,276 shares — an estimated $2.55M sold.

Advisory Research first reported a position in ASND in Q3 2018 and held it in 10 quarters. The position peaked at $2.55M in Q4 2020. 177 funds tracked by Wall St. Rank hold ASND as of Q1 2021.

Advisory Research reported no remaining Ascendis Pharma A/S position as of Q1 2021 after selling out during the quarter.
Advisory Research sold 15,276 Ascendis Pharma A/S shares in Q1 2021, an estimated $2.55M.
Advisory Research first reported a position in Ascendis Pharma A/S in Q3 2018 and held it in 10 quarters.
Advisory Research's Ascendis Pharma A/S position peaked at $2.55M in Q4 2020.
177 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2021.

Based on Advisory Research's 13F filing for Q1 2021, filed 12 May 2021.